Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia.
Steven P TreonKirsten MeidJoshua GustineGuang YangLian XuXia LiuChristopher J PattersonZachary R HunterAndrew R BranaganJacob P LaubachIrene M GhobrialMaria Lia PalombaRanjana H AdvaniJorge J CastilloPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)
Ibrutinib is highly active and produces long-term disease control in previously treated patients with WM. Treatment is tolerable. Response depth, time to major response, and PFS are impacted by MYD88 and CXCR4 mutation status.